Valyltryptophan

Valyltryptophan

SCHEMBL150533

CC(C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.75
ECE1 P42892 12/20 0.72
CTSC P53634 1/20 0.71
ALOX15 P16050 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valyltryptophan SCHEMBL150532 1.00 ACE (0.75) ACEECE1CTSCALOX15
Valyltryptophan SCHEMBL30821963 1.00 ACE (0.75) ACEECE1CTSCALOX15
Valyltryptophan SCHEMBL30821897 1.00 ACE (0.75) ACEECE1CTSCALOX15
Valyltryptophan SCHEMBL29365770 1.00 ACE (0.75) ACEECE1CTSCALOX15
SCHEMBL30051305 0.98 ACE (0.72) ACEECE1CTSCALOX15
SCHEMBL30051858 0.96 ACE (0.69) ACEECE1CTSCALOX15
SCHEMBL30051553 0.95 ACE (0.68) ACEECE1CTSCALOX15
SCHEMBL30052892 0.94 ACE (0.67) ACEECE1CTSC
Hydrochloric Acid SCHEMBL11229707 0.94 ACE (0.67) ACEECE1CTSCALOX15
Valyltryptophan SCHEMBL30641543 0.94 ACE (0.67) ACEECE1CTSC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747264-A1 MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE University of Reading (GB) 2026-05-27 EP claimed
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) 2026-03-12 US claimed
EP-4695413-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF Ohio State Innovation Foundation (US) 2026-02-18 EP claimed
WO-2025037123-A1 MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE UNIVERSITY OF READING (GB) 2025-02-20 WO claimed
CN-118987163-A Use of sardine peptide-containing composition for improving atopic dermatitis symptoms 海口桥水联合科技有限责任公司 2024-11-22 CN claimed
WO-2024235082-A1 USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS 海口桥水联合科技有限责任公司 2024-11-21 WO claimed
US-20240342237-A1 COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION Xygenyx Inc. 2024-10-17 US claimed
WO-2024216031-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2024-10-17 WO claimed
CN-116350746-B Application of sardine peptide composition in medicines for treating allergic rhinitis 海口桥水联合科技有限责任公司 2024-03-22 CN claimed
EP-4310093-A1 AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS, COMPRISING SAME Prazertherapeutics Inc. (KR) 2024-01-24 EP claimed
CN-115397836-A Novel antibacterial peptide and application thereof 安尼根有限公司 2022-11-25 CN claimed
WO-2022196858-A1 AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS, COMPRISING SAME (주)프레이저테라퓨틱스 2022-09-22 WO claimed
CN-114634547-A Dipeptide-2 synthesis process 山东济肽生物科技有限公司 2022-06-17 CN claimed
CN-101795732-A Magnolia extract containing compositions MARY KAY INC 2010-08-04 CN claimed
EP-2144673-A2 MAGNOLIA EXTRACT CONTAINING COMPOSITIONS Mary Kay, Inc. (US) 2010-01-20 EP claimed
WO-2008130752-A2 MAGNOLIA EXTRACT CONTAINING COMPOSITIONS MARY KAY INC. (US) 2008-10-30 WO claimed
US-20080260869-A1 Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin MARY KAY INC. (US) 2008-10-23 US claimed
EP-0084941-B1 AMIDE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-03-11 EP claimed
US-4528282-A Amide derivatives IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1985-07-09 US claimed
EP-0084941-A1 Amide derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-08-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080260869-A1 Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin CUTA, HIRA, VEGFA ACE 2946/4885ECE1 1658/4885CTSC 941/4885
US-20240342237-A1 COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION CUTA, PHLPP1, PHLPP2 ACE 4046/4885ECE1 1737/4885CTSC 249/4885
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis VIP, ANPEP, RNPEP ACE 132/4885ECE1 363/4885CTSC 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.